Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects

Clinical Pharmacology and Therapeutics

Volumn 73, Issue 3, 2003, Pages 264-271

  Chen, Xiao Ping ^b   Tan, Zhi Rong ^b   Huang, Song Lin ^b   Huang, Zheng ^b   Ou Yang, Dong Sheng ^b   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CAFFEINE; CHLORZOXAZONE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; ISOENZYME; MEPHENYTOIN; METOPROLOL; MIDAZOLAM;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SPECIFICITY; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; IN VIVO STUDY; LOW DRUG DOSE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SOMNOLENCE; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; ASPIRIN; CAFFEINE; CHINA; CHLORZOXAZONE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; ISOENZYMES; MALE; MEPHENYTOIN; METOPROLOL; MIDAZOLAM; MIXED FUNCTION OXYGENASES; OXIDOREDUCTASES, N-DEMETHYLATING; PHENOTYPE; REFERENCE VALUES; THEOPHYLLINE;

EID: 0142162559     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2003.14     Document Type: Article

References (29)

1. Patrono C. Aspirin: new cardiovascular uses for an old drug. Am J Med 2001;110:62S-65S.
2. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J Natl Cancer Inst 1998;90:1609-20.
3. Broe GA, Grayson DA, Creasey HM, Waite LM, Casey BJ, Bennett HP, et al. Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch Neurol 2000;57:1586-91.
4. Miners JO. Drug interactions involving aspirin (acetyl-salicylic acid) and salicylic acid. Clin Pharmacokinet 1989;17:327-44.
5. Paxton JW. Effect of aspirin on salivary and serum phenytoin kinetics in healthy subjects. Clin Pharmacol Ther 1980;27:170-8.
6. Fuhr U. Induction of drug metabolising enzymes: pharmacokinetics and toxicological consequences in human. Clin Pharmacokinet 2000;38:493-504.
7. Han XM, Zhou HH. Polymorphism of CYP450 and cancer susceptibility. Acta Pharmacol Sin 2000;21:673-9.
8. Riedl AG, Watts PM, Jenner P, Marsden CD. P450 enzymes and Parkinson's disease: the story so far. Mov Disord 1998;13:212-20.
9. Jagota SK. Depression of cytochrome P450-dependent drug biotransformation by poly(rI.rC) and aspirin. Biochem Med Metab Biol 1989;41:212-6.
10. Cai Y, Sohlenius AK, Andersson K, Sundberg C, DePierre JW. Effects of acetylsalicylic acid on parameters related to peroxisome proliferation in mouse liver. Biochem Pharmacol 1994;47:2213-9.
11. Pankow D, Damme B, Schror K. Acetylsalicylic acid-inducer of cytochrome P-450 2E1? Arch Toxicol 1994;68:261-5.
12. Damme B, Darmer D, Pankow D. Induction of hepatic cytochrome P4502E1 in rats by acetylsalicylic acid or sodium salicylate. Toxicology 1996;106:99-103.
13. Wu D, Cederbaum AI. Sodium salicylate increases CYP2E1 levels and enhances arachidonic acid toxicity in HepG2 cells and cultured rat hepatocytes. Mol Pharmacol 2001;59:795-805.
14. Hakkola J, Tanaka E, Pelkonen O. Developmental expression of Cytochrome P450 enzymes in human liver. Pharmacol Toxicol 1998;82:209-17.
15. Zhu B, Ou-Yang DS, Chen XP, Huang SL, Tan ZR, He N, et al. Assessment of cytochrome P450 activity by a five-drug cocktail approach. Clin Pharmacol Ther 2001;70:455-61.
16. Ou-Yang DS, Huang SL, Xie HG, Wang CY, Zhou HH. Use of caffeine as a probe for rapid determination of cytochrome P-450 CYP1A2 activity in humans. Acta Pharmacol Sin 1998;19:44-6.
17. Xie HG, Huang SL, Zhou HH. High-performance liquid chromatographic determination of urinary 4′-hydroxymephenytoin, a metabolic marker for the hepatic enzyme CYP2C19, in humans. J Chromatogr B Biomed Appl 1995;668:125-31.
18. Huang SL, Xie HG, Wang J, Zhou HH. Determination of metoprolol and α-hydroxymetoprolol in human urine by high performance liquid chromatography with ultraviolet detection. Chin J Chromatogr 1996;14:408-9.
19. Frye RF, Stiff DD. Determination of chlorzoxazone and 6-hydroxychlorzoxazone in human plasma and urine by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1996;686:291-6.
20. Meune C, Mahe I, Mourad JJ, Simoneau G, Knellwolf AL, Bergmann JF, et al. Interaction between angiotensin-converting enzyme inhibitors and aspirin: a review. Eur J Clin Pharmacol 2000;56:609-20.
21. Okita JR, Johnson SB, Castle PJ, Dezellem SC, Okita RT. Improved separation and immunodetection of rat cytochrome P450 4A forms in liver and kidney. Drug Metab Dispos 1997;25:1008-12.
22. Lieber CS. Cytochrome P-4502E1: its physiological and pathological role. Physiol Rew 1997;77:517-44.
23. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001;52:349-55.
24. Yasumori T, Chen LS, Li QH, Ueda M, Tsuzuki T, Goldstein JA, et al. Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: difference in chiral preference of CYP2C9 and CYP2C19. Biochem Pharmacol 1999;57:1297-303.
25. Branch RA, Adedoyin A, Frye RF, Wilson JW, Romkes M. In vivo modulation of CYP enzymes by quinidine and rifampin. Clin Pharmacol Ther 2000;68:401-11.
26. Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waechter F, Fabre JM, et al. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos 2001;29:242-51.
27. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999;37:485-505.
28. Dupont I, Berthou F, Bodenez P, Bardou L, Guirriec C, Stephan N, et al. Involvement of cytochromes P-450 2E1 and 3A4 in the 5-hydroxylation of salicylate in humans. Drug Metab Dispos 1999;27:322-6.
29. Chien JY, Thummel KE, Slattery JT. Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization. Drug Metab Dispos 1997;25:1165-75.